Dinutuximab beta for neuroblastoma, PMID: 33363307
Dinutuximab, PMID: 29999821
Dinutuximab, PMID: 31644006
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial, PMID: 28549783
The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma, PMID: 30433831
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial, PMID: 30442501
Dinutuximab for maintenance therapy in pediatric neuroblastoma, PMID: 28389455
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group, PMID: 32343642
Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma, PMID: 26917818
Dinutuximab: A Review in High-Risk Neuroblastoma, PMID: 26891967
Dinutuximab: first global approval, PMID: 25940913
Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal, PMID: 30465228
Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy, PMID: 30613134
Overview and recent advances in the treatment of neuroblastoma, PMID: 28142287
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1), PMID: 32013055
Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model, PMID: 32096344
Dinutuximab in adult-onset chemotherapy refractory high-risk neuroblastoma, PMID: 32356686
Dinutuximab Synergistically Enhances the Cytotoxicity of Natural Killer Cells to Retinoblastoma Through the Perforin-Granzyme B Pathway, PMID: 32440155
Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma, PMID: 26934530
Dinutuximab and Panobinostat, PMID: 26912916
GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma, PMID: 32246395
Dinutuximab for the treatment of pediatric patients with neuroblastoma, PMID: 29238760
Implementation of immunotherapy into the treatment of neuroblastoma - single center experience with the administration of dinutuximab and management of its adverse effects, PMID: 33108882
Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma, PMID: 32414861
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma, PMID: 20879881
Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice, PMID: 33428582
Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy, PMID: 32733795
Development of a dinutuximab delivery system using silk foams for GD2 targeted neuroblastoma cell death, PMID: 33252182
Quantification of total dinutuximab concentrations in neuroblastoma patients with liquid chromatography tandem mass spectrometry, PMID: 29938370
PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective, PMID: 29196189
Tolerance of dinutuximab therapy for treatment of high-risk neuroblastoma in two patients with end-stage renal disease on dialysis, PMID: 33381917
Patients' NK cell stimulation with activated plasmacytoid dendritic cells increases dinutuximab-induced neuroblastoma killing, PMID: 32342128
Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma, PMID: 30232225
The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology, PMID: 33341446
A Case of Anti-NMDA Receptor Encephalitis During Dinutuximab Therapy for Neuroblastoma, PMID: 31651725
Dinutuximab approved for high-risk neuroblastoma, PMID: 25851859
Optimizing care for high-risk neuroblastoma patients treated with dinutuximab: Challenges for the multidisciplinary team, PMID: 32660378
Extensive small bowel pneumatosis and ischemia during dinutuximab therapy for high-risk neuroblastoma, PMID: 31925911
Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force, PMID: 31031965
Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2 + breast cancer stem-like cells, PMID: 33722905
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma, PMID: 32653773
Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy, PMID: 33392114
In brief: Dinutuximab (Unituxin) for high-risk neuroblastoma, PMID: 27027692
Dinutuximab: A Novel Immunotherapy in the Treatment of Pediatric Patients With High-Risk Neuroblastoma [Formula: see text], PMID: 27456981
Edoxaban, PMID: 26445907
Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States, PMID: 29039999
The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy, PMID: 28061552
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma, PMID: 33303017
G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment, PMID: 34049929
A Phase I/IIa Study of Antidisialoganglioside Antibody Dinutuximab in Japanese Patients With Neuroblastoma, PMID: 31815885
For research use only. Not for human or drug use.
